Sugi Predict

Sugi Predict / Compounds / SCHEMBL9879909

SCHEMBL9879909

SCHEMBL9879909

CC(C)c1ccc(C(C)C)c(N)c1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 6/20 0.39
▸ GABRB1 P18505 4/20 0.39
▸ LMNA P02545 3/20 0.39
▸ GABRB2 P47870 3/20 0.39
▸ SLC6A2 P23975 2/20 0.39
▸ HTR2B P41595 2/20 0.39
▸ GABRG2 P18507 2/20 0.39
▸ GABRB3 P28472 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ FAAH O00519 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542243 0.87 POLB (0.42) GABRA1GABRB1LMNAGABRB2SLC6A2
SCHEMBL830351 0.85 GABRA1 (0.35) GABRA1GABRB1LMNAGABRB2SLC6A2
SCHEMBL19998489 0.83 LMNA (0.38) GABRA1GABRB1LMNAGABRB2SLC6A2
SCHEMBL104314 0.81 GABRA1 (0.55) GABRA1GABRB1LMNAGABRB2SLC6A2
SCHEMBL19972055 0.81 LMNA (0.32) GABRA1GABRB1LMNAGABRB2SLC6A2
SCHEMBL19972025 0.81 GABRA1 (0.54) GABRA1GABRB1LMNAGABRB2SLC6A2
Hydrochloric Acid SCHEMBL8615487 0.79 GABRA1 (0.52) GABRA1GABRB1LMNAGABRB2SLC6A2
SCHEMBL6692957 0.79 GABRA1 (0.52) GABRA1GABRB1LMNAGABRB2SLC6A2
Lithium SCHEMBL30421854 0.79 GABRA1 (0.52) GABRA1GABRB1LMNAGABRB2SLC6A2
SCHEMBL30791052 0.79 GABRA1 (0.52) GABRA1GABRB1LMNAGABRB2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023200800-A1 METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER FOGHORN THERAPEUTICS INC. (US) 2023-10-19 — — WO disclosed
US-20120200808-A1 Polymer compound and polymer light emitting device TOKYO INSTITUTE OF TECHNOLOGY (JP) 2012-08-09 — — US disclosed
EP-0232368-B1 AROMATIC BISMALEIMIDES AND PREPREG RESINS THEREFROM AMOCO CORPORATION (US) 1991-01-16 — — EP disclosed
US-4743647-A Prepreg resin from aromatic bismaleimide and ethylenically unsaturated coreactant AMOCO CORPORATION (US) 1988-05-10 — — US disclosed
EP-0232368-A1 AROMATIC BISMALEIMIDES AND PREPREG RESINS THEREFROM. AMOCO CORP (US) 1987-08-19 — — EP disclosed
US-4654407-A HIGH STRENGTH CASTINGS AMOCO CORPORATION (US) 1987-03-31 — — US disclosed
WO-1987000835-A1 AROMATIC BISMALEIMIDES AND PREPREG RESINS THEREFROM AMOCO CORPORATION (US) 1987-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120200808-A1 Polymer compound and polymer light emitting device MAP1LC3A, MAP1LC3C, MAPRE1 GABRA1 1520/4885GABRB1 1934/4885LMNA 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.